CureVac reports immune response to second cancer vaccine
CureVac GmbH has reported data from an early clinical trial of a second cancer vaccine that is based on messenger RNA (mRNA). The study showed that 65% of patients with non-small cell lung cancer responded to at least one of five antigens.